Santiago Gisler,  —

Linking the small antifibrotic protein interleukin-10 (IL-10) to a hydrogel vehicle allows safe delivery to the lungs of animal models of pulmonary fibrosis. This formulation could be a potential therapy for people with idiopathic pulmonary fibrosis (IPF). The study, “Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung…

Measuring the loss of skeletal muscle mass in the thoracic area using computed tomography (CT) scans may predict clinical outcomes such as survival in patients with idiopathic pulmonary fibrosis (IPF), according to a study. The study, “Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis…

Poor sleep quality — assessed by full-night sleep evaluation and patient questionnaires — is linked to an overall reduced quality of life in individuals with idiopathic pulmonary fibrosis (IPF), according to a study. The study, “Quality of life in idiopathic pulmonary fibrosis: The impact of sleep disordered breathing,”…

Feeding black tea extract to mice in models of pulmonary fibrosis (PF) lessened several disease-associated fibrotic markers, a recent study found. The results suggest black tea extract may have a beneficial therapeutic effect by reducing fibrotic features. The study “Anti-fibrotic effect of black tea (Camellia sinensis) extract in experimental…

A new online platform that pulmonary fibrosis (PF) patients, their friends, family, and caretakers to connect and get information about the disease, was launched recently by the Pulmonary Fibrosis Foundation (PFF) and Responsum Health. The service is free and its purpose is to offer PF patients access to trusted…

Results of a Phase 2b clinical trial suggest actigraphy as a relevant tool to detect meaningful clinical changes in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) when treated with Bellerophon Therapeutics’ product INOpulse. PH-ILD includes PH patients with idiopathic pulmonary fibrosis (PH-IPF). The…

Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with Pharmaxis, may move into Phase 2 trials. Synairgen and Pharmaxis began their collaboration in 2015 to develop…

A small Phase 1 pilot study found improved physical function in idiopathic pulmonary fibrosis (IPF) patients treated with senolytic therapies. The trial was conducted by researchers at University of Texas Health San Antonio, in collaboration with the Mayo Clinic and the Wake Forest School of Medicine. The findings…

A study found a link between MUC5B-induced mucus accumulation and the progression of idiopathic pulmonary fibrosis, reporting that a MUC5B mutation can prevent mucus clearance in the small airways and induce scarring, indicating a strong risk factor in IPF. The study, “Muc5b overexpression causes mucociliary dysfunction and enhances…

Bridge Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) recently approved the company’s Investigational New Drug (IND) application for BBT-877. The company now has permission to start human clinical trials with this potential therapy for idiopathic pulmonary fibrosis (IPF). The IND application was submitted in November 2018.